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Background: Evidence for the comparative teratogenic risk of antiepileptic drugs is insufficient, particularly in relation to the
dosage used. Therefore, we aimed to compare the occurrence of major congenital malformations following prenatal exposure
to the 8 most commonly used antiepileptic drugs in monotherapy. Methods: We did a longitudinal, prospective cohort study
based on the EURAP international registry. We included data from pregnancies in women who were exposed to antiepileptic
drug monotherapy at conception, prospectively identified from 42 countries contributing to EURAP. Follow-up data were
obtained after each trimester, at birth, and 1 year after birth. The primary objective was to compare the risk of major
congenital malformations assessed at 1 year after birth in offspring exposed prenatally to 1 of 8 commonly used antiepileptic
drugs (carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, and valproate) and,
whenever a dose dependency was identified, to compare the risks at different dose ranges. Logistic regression was used to
make direct comparisons between treatments after adjustment for potential confounders and prognostic factors. Findings:
Between June 20, 1999, and May 20, 2016, 7555 prospective pregnancies met the eligibility criteria. Of those eligible, 7355
pregnancies were exposed to 1 of the 8 antiepileptic drugs for which the prevalence of major congenital malformations was
142 (103%) of 1381 pregnancies for valproate, 19 (65%) of 294 for phenobarbital, 8 (64%) of 125 for phenytoin, 107 (55%) of
1957 for carbamazepine, 6 (39%) of 152 for topiramate, 10 (30%) of 333 for oxcarbazepine, 74 (29%) of 2514 for lamotrigine,
and 17 (28%) of 599 for levetiracetam. The prevalence of major congenital malformations increased with the dose at time of
conception for carbamazepine (P ¼ .0140), lamotrigine (P ¼ .0145), phenobarbital (P ¼ .0390), and valproate (P < .0001).
After adjustment, multivariable analysis showed that the prevalence of major congenital malformations was significantly higher
for all doses of carbamazepine and valproate as well as for phenobarbital at doses of more than 80 mg/d than for lamotrigine at
doses of 325 mg/d or less. Valproate at doses of 650 mg/d or less was also associated with increased risk of major congenital
malformations compared with levetiracetam at doses of 250 to 4000 mg/d (odds ratio [OR]: 2.43, 95% confidence interval [CI]:
130-455; P ¼ .0069). Carbamazepine at doses of more than 700 mg/d was associated with increased risk of major congenital
malformations compared to levetiracetam at doses of 250 to 4000 mg/d (OR: 2.41, 95% CI: 1.33-4.38; P ¼ .0055) and
oxcarbazepine at doses of 75 to 4500 mg/d (OR: 2.37, 95% CI: 1.17-4.80; P ¼ .0169). Interpretation: Different antiepileptic
drugs and dosages have different teratogenic risks. Risks of major congenital malformation associated with lamotrigine,
levetiracetam, and oxcarbazepine were within the range reported in the literature for offspring unexposed to antiepileptic
drugs. These findings facilitate rational selection of these drugs, taking into account comparative risks associated with
treatment alternatives. Data for topiramate and phenytoin should be interpreted cautiously because of the small number of
exposures in this study.
Commentary
The teratogenic risks of phenytoin and valproate in humans and
mice were first reported decades ago.1-4 New data on the risks
of all antiepileptic drugs (AEDs) are welcomed by clinicians
and patients, particularly when they include information about
the comparative risks of different medications. These data are
important because the number of cases ascertained in the past
was limited, and because the number of AEDs available in
most countries has increased dramatically over the last 25
years. The latter has resulted in a shift toward the use of newer
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AEDs for which we have few or no data on the risk of human
teratogenesis.
Most women with epilepsy (WWE) and their providers are
aware that AEDs as a group carry an increased risk of major
congenital malformations (MCMs), yet some lack the most up-
to-date information about risks specific to the AED and the
dose being used in their pregnancy. As a result, some pregnan-
cies are being managed today on the basis of older, possibly
inaccurate or incomplete information. Given that AEDs are
used not only for epilepsy but also to treat chronic migraine,
bipolar disorder, neuropathic pain, fibromyalgia, and some-
times off-label for other conditions, the number of potential
parents and their offspring who may benefit from updated
information is quite large. For these reasons it is important to
provide access to accurate and current risk data not only to
neurology providers but also to all health-care practitioners
in order to reduce the risks of a lifetime of morbidity caused
by the use of AEDs during pregnancy. To address these con-
cerns, several international AED pregnancy registries were
established approximately 2 decades ago.
The North American AED Pregnancy Registry (NAAPR)
began enrollment in February 1997. Pregnant women taking
AEDs for any reason may enroll prior to delivery, preferably
prior to any prenatal screening. The AEDs taken in the first
trimester are studied. Women register themselves, and outcome
is verified shortly after delivery by obtaining the medical
records of the mother and infant. Additionally, an internal con-
trol group of pregnant women who were not taking AEDs is
enrolled. Rates of major malformations are assessed; excluded
are minor anomalies, such as preauricular sinus, simian creases,
hemangiomata, congenital skin moles, undescended testes, pat-
ent ductus arteriosus, Down syndrome, achondroplasia, hip
dysplasia with breach, and unilateral renal agenesis seen only
on ultrasound.5
The most recent NAAPR results were updated on October
31, 2018 and are available online via open-access.6 For the 8
most-commonly used AEDs in North America, 5925 pregnant
WWE have provided pregnancy outcome data for monotherapy
use. The incidence of MCMs (numbers in parentheses are 95%
confidence intervals [CI]) were 8.2% (5.5-11.9%) for valpro-
ate, 6.1% (3.3-10.7%) for phenobarbital, 5.3% (3.6-7.9%) for
topiramate, 2.8% (1.9-4.0%) for carbamazepine, 2.6% (1.4-
4.7%) for phenytoin, 2.6% (1.2-5.6%) for oxcarbazepine,
2.1% (1.5-2.8%) for lamotrigine, and 2.0% (1.3-3.1%) for leve-
tiracetam. The MCM rate for the internal control group of 745
unexposed women was 1.2% (0.6%-2.4%).
Enrollment in the NAAPR by year for specific AEDs has
changed dramatically. In 1999, the proportion of mothers
receiving carbamazepine was *45%, phenytoin was *20%,
valproate was *15%, and phenobarbital was *10%. In 2018,
lamotrigine was 40%, levetiracetam was *35%, gabapentin
was *8%, and others were each 5% or less (valproate was
*0%). There is no doubt that early results from the NAAPR
and other international registries informed changes in the pre-
scribing choices of providers.
The UK and Ireland Epilepsy and Pregnancy Registers,
established in December 1996, also enroll pregnant women
taking AEDs and WWE who were not taking medication prior
to delivery. Pregnancy, epilepsy, and outcome information are
obtained at the time of registration and also at 3 months post-
partum. Eligible pregnant women are referred by their health-
care provider or by themselves. Outcomes are classified as: no
birth defects, MCMs, or other defects (minor defects, chromo-
somal disorders, and single gene defects). A 2014 publication7
reported 15 years of data regarding the occurrence of MCMs in
5206 women exposed to monotherapy valproate (n ¼ 1290),
carbamazepine (n ¼ 1718), and lamotrigine (n ¼ 2198). The
MCM risk with monotherapy valproate was 6.7% ( CI ¼ 5.5%-
8.3%) versus 2.6% with carbamazepine (1.9%-3.5%), and 2.3%
with lamotrigine (1.8%-3.1%). A significant dose-effect was
seen with valproate (P ¼ .0006) and carbamazepine (P ¼
.03). A non-significant trend toward higher MCM rate with
increasing dose was found for lamotrigine, but the MCM rate
for high-dose lamotrigine (>400 mg/d) was still lower than the
rate for low-dose valproate (<600 mg/d; 3.4% vs 5.0%, respec-
tively; N.S.).
The Australia Register of AEDs in Pregnancy (ARAP)
began in 1999, and reported its first 15 years of experience in
1461 pregnancies with AED monotherapy and 484 pregnancies
with AED polytherapy.8 The ARAP found that MCM rates
decreased from 1999 to 2014 in monotherapy but increased
in polytherapy pregnancies despite less frequent use and lower
doses of valproate. The MCMs became more frequent in poly-
therapy pregnancies around 2005 when topiramate and levetir-
acetam use increased. When pregnancies involving valproate
were excluded, MCM rates were still higher in the remaining
polytherapy pregnancies than the monotherapy ones (6.90% vs
3.64%; odds ratio 1.96, 95% CI: 1.23-5.10). Levetiracetam in
polytherapy did not result in increased malformation rates.
Topiramate in polytherapy had a positive dose-relationship
with teratogenicity risk (P ¼ .025). The methodology for
ARAP is similar to the NAAPR.
The Kerala (India) Registry of Epilepsy and Pregnancy,
established in 1998, published its findings of 1021 monother-
apy and 368 dual AED exposures in pregnancy through 2013.9
The AEDs used most commonly were carbamazepine, valpro-
ate, phenobarbital, and clobazam. The MCMs occurred in 70
(6.8%) of monotherapy and 44 (11%) of dual therapy exposed
pregnancies. Valproate had a higher rate of MCMs than other
monotherapies. The excess risk of dual therapy over monother-
apy (relative risk ¼ 1.6, P ¼ .0015) was largely contributed by
topiramate or valproate.
The International Registry of AEDs and Pregnancy
(EURAP), established in 1999 in Europe, is now a consortium
of 44 countries from Europe, Oceania, Asia, Latin America, and
Africa. Pregnant WWE are included if they are exposed to AEDs
at conception, are enrolled by their health-care provider by
gestational week 16, and have known fetal outcome and out-
comes reported by their provider at the end of each trimester, and
at birth, 2 months, and 1 year of age. Exclusion criteria are
women without epilepsy, cases in which data were not reported
84 Epilepsy Currents 19(2)
within preset deadlines, pregnancies in which AEDs were with-
drawn or switched during the first trimester, AED polytherapy,
exposure to other teratogenic drugs, spontaneous abortions,
abortions induced for etiologies other than fetal malformations,
and offspring with genetic or chromosomal abnormalities.
The current EURAP report by Tomson et al summarizes its
most current findings on the teratogenic risks of the 8 AEDs
most commonly used in monotherapy. 7335 of prospective
pregnancies met inclusion criteria and were exposed. The pre-
valence of MCMs was greater for 7 of the 8 monotherapy
AEDs than in the recent NAAPR update. The only exception
was the rate for topiramate, which was lower in the EURAP
than the NAAPR registry. Differences in registry methodolo-
gies likely account for the generally higher rates in EURAP.
The NAAPR ascertains women using self-referral, and obtains
pregnancy outcome data shortly after delivery. By contrast,
EURAP enrolls women via their health-care provider, and final
outcome assessment is at 1 year. As a result of having women
self-enroll in NAAPR, a bias toward inclusion of women who
are more motivated regarding their pregnancy and have better
prenatal care may occur, thereby including women who may
have a lower chance for a malformation. Likewise, by obtain-
ing MCM outcome data at 1 year of age of the infant, the
EURAP study may have a greater chance to detect birth defects
which were missed shortly after birth.
Considering only these 5 international registries, and not
including others,10 more than 20 000 WWE taking or not taking
AEDs, and women taking AEDs for other conditions, have
contributed vitally important data with which we can better
counsel future patients. Although the exact prevalence rates
of MCMs for each of the major AEDs reported vary somewhat
across the registries, most likely due to differences in enroll-
ment criteria and follow-up methodologies, the relative risks
are generally consistent.
It’s abundantly clear that of the AEDs studied in large num-
bers, valproate carries the highest risk of MCMs. Furthermore,
valproate exposure has been linked with a higher incidence of
developmental intellectual disability, and in some studies aut-
ism.11 This has led the US Food and Drug Administration and
the European Medicines Agency to issue mostly concordant
warnings and contraindications to the prescribing information
for valproate. In response, on 12 May 2017, the American
Epilepsy Society created a position statement about the use
of valproate by women of childbearing potential and can be
found at www.aesnet.org.
In summary, the monotherapy MCM prevalence rate with
valproate is highest, the rates with topiramate and phenobarbi-
tal are moderately high, the rates with carbamazepine, oxcar-
bazepine, and phenytoin are intermediate, and the rates with
levetiracetam and lamotrigine are lowest, but all have higher
risk than the NAAPR internal control rate of 1.2%. Higher
doses correlate with higher MCM rates with valproate and
carbamazepine in monotherapy, and with topiramate in poly-
therapy. Higher dose lamotrigine monotherapy has a nonsigni-
ficant trend toward a higher MCM rate. Polypharmacy results
in higher prevalence rates of MCMs, particularly when these
regimens include valproate or topiramate.
The results of these studies provide extremely helpful infor-
mation to guide the management of the pregnant woman taking
AEDs. These important registries must continue to enroll more
patients in order to provide needed information about the risk
of human teratogenesis with the use of the newest medications.
By David G. Vossler
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